Showing results (1231-1240 of 1,350) with videos related to

Sort By:
Pageof 135
Advanced Healthcare Materials|October 10, 2013
Combined surface micropatterning and reactive chemistry maximizes tissue adhesion with minimal inflammationMaria J N Pereira, Cathryn A Sundback, Nora Lang, et al.
Journal of the Pediatric Infectious Diseases Society|November 18, 2022
The Prevalence of Symptomatic Congenital Cytomegalovirus Disease in Korea; A 15-Year Multicenter Study and Analysis of Big Data From National Health Insurance SystemSae Rom Choi, Kyung-Ran Kim, Sohee Son, et al.
International Journal of Radiation Oncology, Biology, Physics|December 13, 2024
Concurrent Versus Sequential Adjuvant Capecitabine-Based Chemoradiation in Residual Triple-Negative Breast Cancer After Neoadjuvant-Chemotherapy: A Multicenter Comparative StudyNalee Kim, Su Ssan Kim, Won Kyung Cho, et al.
Annals of the Rheumatic Diseases|February 1, 2025
Genetic burden of lupus increases the risk of transition from normal to preclinical autoimmune conditions via antinuclear antibody developmentSehwan Chun, So-Young Bang, Ayeong Kwon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 6, 2025
Predicting 30-day mortality with routine blood tests in patients undergoing palliative radiation therapy: A comparison of logistic regression and gradient boosting modelsTae Hoon Lee, Sang Hoon Seo, Hyunju Shin, et al.
The Korean Journal of Internal Medicine|January 26, 2007
Thalidomide for treating metastatic hepatocellular carcinoma: a pilot studySang Hoon Han, Se Hoon Park, Jung Ho Kim, et al.
International Journal of Rheumatic Diseases|January 25, 2019
Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant valuesMin Kyung Chung, Bohyun Park, In Je Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialKaren Kelly, Nasser K Altorki, Wilfried E E Eberhardt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC PatientsGiorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, et al.
Medicine|April 4, 2015
Prospective, randomized comparison of same-day dose of 2 different bowel cleanser for afternoon colonoscopy: picosulfate, magnesium oxide, and citric acid versus polyethylene glycolTae-Geun Gweon, Sang Woo Kim, Yong-Sun Noh, et al.
Pageof 135